COVID-19 With Influenza A/B and Respiratory Syncytial Virus, NAA
Nucleic Acid Amplification (NAA)
This test is designed to simultaneous qualitative detection and identification of nucleic acids of Influenza A/B, Respiratory Syncytial Virus and SARS-Cov-2 in nasopharyngeal swabs obtained from individuals suspected of respiratory tract infections.
Influenza A virus Panel (H1 and H3)
Influenza A virus H1-2009
Influenza A virus H3
Influenza B virus
Respiratory Syncytial Virus
Specimen type: Anterior nasal swab; nasopharyngeal Swab, mid-turbinate swab
Volume: One swab in viral transport, 0.3 mL minimum
Container: Viral Transport System
Storage Instructions: Per the package insert: Swabs in viral transport media are stable for 30 days at -15°C or below. Swabs in viral transport media are also stable for 4 hours at room temperature and 3 days refrigerated (2º to 8º C).
Causes for Rejection: Improper collection; inadequate specimen; improper labeling; specimen leaked in transit; quantity not sufficient for analysis; name discrepancies; specimen exceeding storage requirements; specimen types other than nasopharyngeal swab in viral transport media
This test has been validated according to the FDA guidelines, by CLIA # 45D2209248. Our laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C section 263a, to perform high complexity tests. The assay is validated internally by COLA guidance. Test performance can be affected because the clinical spectrum of infection caused by SARS-CoV-2 is not fully known.
Expected Turnaround Time
1 day. Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider.